The role of cell junctions in atherosclerosis: implications for inflammation, endothelial dysfunction, and plaque stability
- PMID: 40614036
- DOI: 10.1007/s13105-025-01106-6
The role of cell junctions in atherosclerosis: implications for inflammation, endothelial dysfunction, and plaque stability
Abstract
Atherosclerosis, a chronic inflammatory disease, involves a complex interplay between endothelial cells, smooth muscle cells, and inflammatory mediators. Cell-to-cell junctions, including adherens junctions (AJs), tight junctions (TJs), and gap junctions (GJs), play a critical role in maintaining vascular integrity and regulating cellular interactions in the vascular wall. This review summarises the molecular mechanisms by which these junctions contribute to atherosclerosis, focusing on key proteins like VE-cadherin (AJs), ZO-1, occludin, and claudins (TJs), and connexins (GJs). Dysregulation of these junctions, driven by factors such as oxidative stress, pro-inflammatory cytokines, atheroprone shear stress (aSS), and lipid-mediated signalling pathways, leads to endothelial dysfunction, increased permeability, monocyte infiltration, and plaque instability. Furthermore, the role of signalling pathways, including NFκB, PI3K/AKT, and Wnt/β-catenin, in the regulation of junctional proteins is explored. Emerging factors, including oxygenated cholesterol, radiation, and various drugs, provide new insights into junctional modulation in atherosclerosis. The potential of targeting junctional proteins and their associated pathways for therapeutic interventions is also discussed. Future studies focusing on the detailed mechanisms of junctional dysregulation in vivo and the clinical translation of these findings are necessary to develop novel therapeutic strategies for atherosclerosis. Clinical trial number Not applicable.
Keywords: Adherens junctions; Atherosclerosis; Cardiovascular diseases; Connexin; Endothelial dysfunction; Inflammation; Tight junctions; VE-cadherin.
© 2025. The Author(s) under exclusive licence to University of Navarra.
Conflict of interest statement
Declarations. Ethical approval: Not applicable. Informed consent: Not applicable. Competing interests: The authors declare no competing interests.
References
-
- Bergström G, Persson M, Adiels M, Björnson E, Bonander C, Ahlström H, Alfredsson J, Angerås O, Berglund G, Blomberg A et al (2021) Prevalence of subclinical coronary artery atherosclerosis in the general population. Circulation 144:916–929. https://doi.org/10.1161/CIRCULATIONAHA.121.055340 - DOI - PubMed - PMC
-
- Jebari-Benslaiman S, Galicia-García U, Larrea-Sebal A, Olaetxea JR, Alloza I, Vandenbroeck K, Benito-Vicente A, Martín C (2022) Pathophysiology of Atherosclerosis. IJMS 23, 3346. https://doi.org/10.3390/ijms23063346
-
- Medina-Leyte DJ., Zepeda-García O, Domínguez-Pérez M, González-Garrido A, Villarreal-Molina T, Jacobo-Albavera L (2021) Endothelial dysfunction, inflammation and coronary artery disease: potential biomarkers and promising therapeutical approaches. IJMS 22:3850. https://doi.org/10.3390/ijms22083850
-
- Malekmohammad K, Bezsonov EE, Rafieian-Kopaei M (2021) Role of lipid accumulation and inflammation in atherosclerosis: focus on molecular and cellular mechanisms. Front Cardiovasc Med 8:707529. https://doi.org/10.3389/fcvm.2021.707529 - DOI - PubMed - PMC
-
- Mezentsev A, Bezsonov E, Kashirskikh D, Baig MS, Eid AH, Orekhov A (2021) Proatherogenic Sialidases and desialylated lipoproteins: 35 years of research and current state from bench to bedside. Biomedicines 9:600. https://doi.org/10.3390/biomedicines9060600 - DOI - PubMed - PMC
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous